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Abstract 
 
Objectives: To evaluate whether a hand-held creatinine analyser (StatSensor® Xpress; SSXp), 
available for human patients, can be used to reliably measure creatinine in cats. 
 
Methods: Analytical performance was evaluated by determining within-run and between-run 
coefficient of variation (CV, %), total error observed (TEobs, %) and sigma metrics. 50 client-owned 
cats presenting for investigation of clinical disease had creatinine measured simultaneously, using 
SSXp (whole blood and plasma) and a reference instrument (Konelab, serum); 48 paired samples 
were included in the study. Creatinine correlation between methodologies (SSXp vs Konelab) and 
sample types (SSXpwhole blood vs SSXpplasma) was assessed by Spearman’s correlation coefficient and 
agreement was determined using Bland-Altman difference plots. Each creatinine value was assigned 
an IRIS stage (1-4); correlation and agreement between Konelab and SSXp IRIS stages was evaluated.  
 
Results: Within-run CV (4.23-8.85%), between-run CV (8.95-11.72%), TEobs (22.15-34.92%) and 
sigma metrics (≤3) did not meet desired analytical requirements. Correlation between sample types 
was high (SSXpwhole blood vs SSXpplasma; r = 0.89) and between instruments was high (SSXpwhole blood vs 
Konelabserum; r = 0.85) to very high (SSXpplasma vs Konelabserum; r = 0.91). Konelab and SSXpwhole blood 
IRIS scores exhibited high correlation (r = 0.76). PCV did not significantly affect SSXp determination 
of creatinine. Bland-Altman difference plots identified a positive bias for the SSXp (7.13µmol/l 
SSXpwhole blood; 20.23µmol/l SSXpplasma) compared with the Konelab. Outliers (1/48 whole blood; 2/48 
plasma) occurred exclusively at very high creatinine concentrations. The SSXp failed to identify 2/21 
azotaemic cats. 
 
Conclusions and relevance:  Analytical performance of the SSXp in feline patients is not considered 
acceptable. The SSXp exhibited high to very-high correlation compared to reference methodology 
but the two instruments cannot be used interchangeably. Improvements in SSXp analytical 
performance are needed before its use can be recommended in feline clinical practice. 
Introduction 
 
Chronic kidney disease (CKD) is highly prevalent within the feline population, affecting up to 20% of 
clinic-attending cats, with increasing incidence with age.1,2 The disease is invariably progressive and 
remains an important cause of morbidity and mortality, particularly within the geriatric 
population.3,4,5  Recent literature has explored the incidence of occult, hospital acquired, acute kidney 
injury (HA-AKI) and identified a prevalence within the feline population of up to 21.2%.6 Despite a 
trend towards evaluating more sensitive serum and urine biomarkers of renal disease, creatinine 
remains an important diagnostic marker.7,8  
 
Point-of-care (PoC) creatinine testing has found utility in human medicine in both screening 
programmes for the prevalence of CKD and early identification of kidney injury in at-risk 
patients.9,10,11 PoC analyzers typically have small sample requirements and a rapid turnaround time,  
providing real-time clinical information.11-15 
 
A PoC creatinine analyzer is an attractive tool in feline clinical practice, given the high incidence of 
CKD in this species and their relative risk of kidney injury. Various publications have assessed the 
use of PoC creatinine analyzers in human medicine and a single abstract reports their use in dogs.16 
To the authors’ knowledge, such devices have not previously been evaluated in cats.  We evaluated a 
hand-held analyser that is available for use in human patients; the ‘StatSensor® Xpress-iTM Creatinine 
Hospital Meter’ (SSXp; Nova Biomedical Corporation, Waltham, MA, USA). The aims of this study 
were (1) to perform imprecision studies using the SSXp to determine whether device performance 
was acceptable for the measurement of creatinine in cats and (2) to compare the results obtained 
from clinical samples using the SSXp to those generated from a commercial high-throughput wet 
chemistry analyzer (Konelab PRIME 60, Thermo Scientific, Finland). Ethical approval was granted 
for the study by the University of Bristol Ethics Committee. 
 
Materials and Methods 
Clinical cases and samples 
Privately owned cats presented to The Feline Centre at Langford between January 2013 and January 
2014, for investigation of clinical disease, were eligible for inclusion. Blood (1.5-3ml, jugular 
venepuncture) was collected into an EDTA tube (TEKLAB, 0.5 ml) for routine haematology and a non-
anticoagulant (plain) tube (BD Vacutainer, 1-2.5ml) for serum biochemical analysis, which included 
creatinine measurement using the Konelab analyser (Konelabserum). The remaining blood was used 
for immediate creatinine measurement by the SSXp (1.2µl whole blood [SSXpwhole blood]) and then to 
fill a microhaematocrit tube (NRIS microhaematocrit tubes, Soda Lime Glass Na-Heparinized [80 
iu/ml], Vitrex Medical) to enable centrifugation for determination of packed cell volume (PCV) and 
measurement of creatinine in the supernatant plasma using the SSXp (SSXpplasma).   
Icteric, haemolysed or lipaemic samples were excluded from analysis due to known interferences of 
bilirubin, haemoglobin and lipaemia with the creatinine methodology employed by the Konelab, and 
the lack of information regarding the effect of these interferences on the SSXp methodology.17 
 
For the imprecision studies, a pooled serum sample was created using excess serum from clinical 
samples, stored in frozen aliquots; this sample was first analyzed in duplicate using the Konelab to 
confirm that the creatinine concentration was within the analytical range of the SSXp. 
 
StatSensor Xpress 
The SSXp is a small hand-held battery powered device that utilizes amperometric methodology, 
detecting H2O2 elimination from an immobilized three-enzyme membrane. Single-use Multi-WellTM 
technology reagent test strips are inserted into the device. Delivery of the clinical sample fills the test 
strip by capillary action. An audio sound confirms sample receipt and the creatinine concentration 
(µmol/l or mg/dl) is displayed after 30 seconds. The reported measurable creatinine range is 27-
1056 µmol/l (0.31-11.95mg/dl); results outwith this are reported as ‘Hi’ or ‘Lo’.  
 
Three quality control solutions (StatSensor Creat Control C1, C2, C3; Nova Biomedical [QCM]) were 
provided which were run daily and each time a new canister of strips was opened.18 The purpose of 
this was to evaluate device performance prior to sample analysis. In the event of QCM results outside 
the provided reference interval, algorithms for device calibration were available from the 
manufacturer. 
 
Konelab 
Creatinine concentration was measured in serum samples using an enzymatic colorimetric 
methodology.  Calibration procedure and sample analysis were performed according to the 
manufacturer’s instructions.17 Control material (Biostat Diagnostic Systems) with low, normal and 
high values was included in every run of Konelab samples. Methodology accuracy was assessed by 
continuous bimonthly participation in an external quality assurance programme (RIQAS; Randox). 
The measuring range is 10-2500µmol/l (0.11-28mg/dl), extending to 10,000µmol/l (113mg/dl) 
following dilution. Imprecision is ≤4.5% total CV; within-run and between-day CV range from 0.4-
1.4% and 0.3-0.5%, respectively. This laboratory’s established reference interval for feline serum 
creatinine was 133-175µmol/l (0.37-1.98mg/dl).  
 
Imprecision 
Imprecision is the lack of repeatability of a result, during sequential analysis of a sample and is 
expressed as coefficient of variation (CV; %).19  
SSXp imprecision was assessed by within- and between-run repeatability using the three QCM and 
the serum pool. 
Within-run repeatability was determined by measuring creatinine in the same sample 20 times 
sequentially (QCM and feline serum pool). 
Between-run repeatability was determined from the values generated over a 20 day period (QCM) 
and by measuring creatinine in duplicate daily for five consecutive days (feline serum pool).19  
 
Sample type and method comparisons 
On each day of testing, SSXpwhole blood was analysed immediately following sample collection and 
SSXpplasma within 15-30 minutes afterwards. Plain tubes were transported to the Diagnostic 
Laboratories where Konelabserum was run within 45-60 minutes post blood collection.  
  
Data collection and statistical analysis 
Data regarding the date of sample acquisition, cats’ signalment, disease, creatinine results and PCV 
were recorded in a commercially available spreadsheet (Microsoft Excel, USA). All statistical analyses 
were performed using the 2D graphing and statistics software Prism® 4 GraphPad (GraphPad 
Software Inc., USA).  
 
Imprecision, total error observed (TEobs) and sigma (σ) metrics 
Within- and between-run imprecision were determined by calculating the CV (%): 
CV = 100 × standard deviation (SD)/ mean 
Total error observed (TEobs; %) is the sum of random error (imprecision) and systematic error, with 
the former represented by CV and the latter represented by bias (inaccuracy of the generated result 
compared to the true value). TEobs for creatinine was determined by the following formula:19  
TEobs(%) = 2 × CV + bias(%) 
Bias was calculated using the QCM according to the following formula:  
Bias(%) = (target-measured)/target 
Where ‘target’ is the mean creatinine value reported by the manufacturer and ‘measured’ is the mean 
creatinine value measured by the SSXp over the 20 day period.18  
Since three different QCM (C1, C2, C3) were used daily, bias was determined from each of the three 
controls. 
TEobs was assessed in two ways: (1) TEobs(%) values for each of the QCM [TEobs-C1 , TEobs-C2,  TEobs-C3] 
were calculated using the specific between-run CV and bias for each QCM as determined above; (2) 
feline-specific TEobs(%) was calculated using the between-run CV for the feline serum pool and each 
one of the three QCM bias as determined above. Since bias was determined for C1, C2 and C3, feline-
specific TEobs-C1(%), TEobs-C2(%) and TEobs-C3(%) were calculated for comparison. SSXp methodology 
was considered acceptable if TEobs < total allowable error (TEA). Since published TEA values vary 
throughout the literature, these were taken from the guidelines of the American Society for 
Veterinary Clinical Pathology (ASVCP) (TEA: 20%) and published studies (TEA: 17%).19,20 
Sigma metric values (σ), a universally-accepted objective measure of analytical methodologies, were 
calculated according to the following formula:19,20,21  
σ = (TEA[%] – bias[%])/ CV 
TEA values were taken from published studies, bias was taken as the bias for the QCM C1 and CV as 
the between-run CV for the feline pool.19,20 As the TEA values differed between the two sources (17% 
vs 20%), σ was calculated for both to generate one for the low (σLow) and one for the higher (σHigh) 
TEA value. Interpretation of σ values was performed as follows: ≤3: poor; >3: marginal; >4: good; >5: 
excellent; >6: world-class.22,23 
 
Sample type and method comparisons 
Relationships between creatinine values for each collected set of data (Konelabserum vs SSXpwhole blood, 
Konelabserum vs SSXpplasma, SSXpwhole blood vs SSXpplasma) were evaluated for normality using the 
D’Agostino-Pearson omnibus normality test.  
Using the same data sets, Spearman’s correlation coefficient was calculated to measure the strength 
of relationship between (a) methodologies (SSXp vs Konelab), (b) SSXp values obtained from 
different sample types (whole blood vs plasma) and (c) PCV and SSXpwhole blood creatinine results. To 
further explore the clinical applicability of the device, every creatinine value was also assigned an 
IRIS stage (<140µmol/l [<1.6mg/dl] = IRIS stage 1; 140-250µmol/l [1.6-2.8mg/dl] = IRIS stage 2; 
251-440µmol/l 2.9-5.0mg/dl] = IRIS stage 3; >440µmol/l [>5.0mg/dl] = IRIS stage 4) and correlation 
of IRIS staging between methodologies (Konelab vs SSXp) was evaluated, with IRIS stage 1 
considered non-azotemic and IRIS stages 2-4 considered azotemic.24 Correlation coefficients were 
interpreted as proposed by Zady: 0.9-1 very high correlation, 0.70-0.89 high correlation, 0.50-0.69 
moderate correlation, 0.30-0.49 low correlation and <0.30 little, if any, correlation.25 
Sensitivity and specificity for the SSXp’s ability to determine non-azotemic vs azotemic samples 
(using a cut-off of 140µmol/l, based upon IRIS staging) were calculated using the following formulae: 
Sensitivity = true positive results / (true positive results + false negative results) 
Specificity = true negative results / (true negative results + false positive results) 
Deming regression analysis was used to determine the mathematical relationship and the constant 
(intercept) and proportional (slope) error of the SSXp relative to the Konelab and SSXpplasma relative 
to the SSXpwhole blood values.   Bland-Altman analysis was used to assess agreement between the two 
instruments and between SSXp results obtained from the two different sample types.26 Agreement 
was considered good when the 95% limits of agreement (LOA; mean of the differences ±2SD) were 
narrow and the bias was small.  
 
Results 
Clinical cases 
50 samples from 44 cats were analysed for inclusion in the study. Two samples, both from the same 
cat on different occasions, were visibly icteric, thus excluded from analysis. No sample was visibly 
haemolysed or lipaemic. Of the 43 cats included in the study, ages ranged from 1 year 1 month to 16 
years (median 9 years 11 months). There were 20 male neutered, one male entire and 22 female 
neutered cats of a variety of breeds; 33 Domestic Shorthair, two Domestic Longhair, two British 
Shorthair, two Persian and one each of Burmese, Norwegian Forest, Siamese and Somali. Thirty one 
of the 43 cats presented for a single clinical problem and 12 had multiple clinical problems, 
encompassing a variety of diseases; endocrine (20), urinary tract (15), respiratory (6), cardiac (6), 
hepatic (4), neurological (3), nutritional (2), gastro-intestinal (2), neoplastic (1) and haematological 
(1). 
 
StatSensor 
No technical problems occurred when using the device. The error code ‘E-4’, indicating insufficient 
sample, occurred three times during precision analysis and repeatability; repeat samples were 
successfully measured. No error codes occurred whilst measuring clinical samples.  
Manufacturer provided target ranges for C1, C2 and C3 QCM were 44-124µmol/l, 133-239µmol/l and 
398-663µmol/l (0.50-1.40mg/dl, 1.50-2.70mg/dl and 4.50-7.50mg/dl), respectively. No QCM 
failures were identified during the study; every result was within its designated range.  
 Imprecision, total error observed (TEobs) and sigma (σ) metrics 
The imprecision studies identified SSXp imprecision (CV, %) within- and between-run of 4.23-8.85% 
and 8.95-11.72% respectively (Table 1).  
 
CV (%) C1 
Mean target: 
84µmol/l 
(0.95mg/dl) 
C2 
Mean target: 
186µmol/l 
(2.10mg/dl) 
C3 
Mean target: 
530µmol/l 
(6.00mg/dl) 
Serum pool 
 
Within-run  6.32 8.85 5.07 4.23 
Between-run 11.72 10.13 10.23 8.95 
Table 1: Precision values (CV, %) for creatinine measurement by the SSXp, as determined by within-run 
and between-run CV for the three levels of QCM and the pooled feline serum sample 
CV, coefficient of variation (%); QCM, quality control media; C1, C2 and C3, levels 1, 2 and 3 QCM, 
respectively 
 
Quality requirements 
Average (mean) TEobs (between-run) for QCM was 29.36 (range 22.15-34.92) and for the feline serum 
pool was 25.87 (range 19.78-29.39) (Tables 2 and 3). No within-run QCs fell outside 20% of the mean 
target value. 5/20 C1, 1/20 C2 and 5/20 C3 between-run QCs fell outside 20%.  
 
 QCM TEA (%) 
 Bias Bias Bias TEobs-C1 TEobs-C2 TEobs-C3  
C1 C2 C3 
Creatinine -11.49 1.88 10.55 34.92 22.15 31.00 17, 20 
Table 2: Calculated bias and TEobs of the SSXp at all three level QCM (C1, 2 and 3) 
QCM, quality control media; TEA, total allowable error; TEobs, total error observed; TEobs-C1-3, total error 
observed for each of the three QCM 
 
 Serum pool TEA (%) 
 TEobs-C1 TEobs-C2 TEobs-C3 SigmaLow SigmaHigh  
Creatinine 29.39 19.78 28.45 0.616 0.951 17, 20 
Table 3: Calculated total error observed and sigma metrics of creatinine measurement of the feline 
serum pool by the SSXp 
TEA, total allowable error; TEobs, total error observed; SigmaLow, sigma metrics calculated for TEA of 
17%; SigmaHigh, sigma metrics calculated for TEA of 20% 
 
Creatinine 
Analysis of the 48 clinical samples generated a wide range of Konelab creatinine values (range: 48-
1299µmol/l [0.54-14.69mg/dl], median: 129.5µmol/l [1.46mg/dl]), reflecting all IRIS CKD stages 
(stage 1: 27 samples, stage 2: 17, stage 3: one, stage 4: three) thus enabling evaluation of SSXp 
performance across a wide range of creatinine concentrations.  
The range of creatinine results generated by the SSXp on clinical samples was 63-682µmol/l (0.71-
7.71mg/dl; median 141µmol/l [1.60mg/dl]) for SSXpwhole blood and 73-664µmol/l (0.83-7.51mg/dl; 
median 170.5µmol/l, [1.93mg/dl]) for SSXpplasma. No ‘Hi’ or ‘Lo’ results were generated.  
 
Comparison studies 
Comparing SSXp and Konelab, very high correlation was demonstrated between SSXpplasma and 
Konelabserum (r = 0.91, P<0.0001) and high correlation between SSXpwhole blood and Konelabserum (r = 
0.85, P<0.0001). LOA were very wide (474.6 µmol/l [5.37mg/dl] and 433.6µmol/l [4.90mg/dl] 
respectively). Similarly high correlation was demonstrated between SSXpwhole blood and SSXpplasma (r = 
0.89, P<0.0001, although again, with relatively wide LOA; 206.78µmol/l [2.34mg/dl]).  There was no 
statistically significant correlation between PCV and SSXpwhole blood creatinine values (r = -0.28), 
across the tested range (PCV 18-42%). These findings are shown in Tables 4 and 5.  
SSXpwhole blood determination of azotemia (compared to Konelabserum) as based on IRIS staging 
(creatinine ≥140µmol/l [≥1.6mg/dl]) had sensitivity of 90% and specificity of 82%. 
 
 r 95% CI P value 
a) Konelabserum vs SSXpwhole blood (n=48) 0.85 0.73 – 0.91 <0.0001 
b) Konelabserum vs SSXpplasma  (n=48) 0.91 0.85 – 0.95 <0.0001 
c) SSXpwhole blood vs SSXpplasma (n=48) 0.89 0.82 – 0.94 <0.0001 
d) PCV vs SSXpwhole blood  (n=46) -0.28 -0.53 – 0.02 0.0609* 
e) Konelabserum vs SSXpwhole blood (IRIS stages) (n=48) 0.76 0.61-0.86 <0.0001 
Table 4. Comparison studies, as expressed by Spearman’s correlation coefficient and 95% confidence 
intervals for creatinine measurement between different methodologies (Konelab vs SSXp) (a, b), 
creatinine measurement between different matrices (SSXpwhole blood vs SSXpplasma) (c), creatinine 
measurement vs PCV (d) and IRIS stages between different methodologies (Konelab vs SSXp) (e) 
r, Spearman’s correlation coefficient; CI, confidence interval; *, not statistically significant 
 
Constant error, proportional error and bias for the SSXp relative to the Konelab and SSXpplasma 
relative to the SSXpwhole blood values are presented in Table 5 and Figures 1(a-d) and 2(a,b). 
 Deming regression 
 
Bland-Altman  
Slope 95%CI y-
intercept 
95% CI Bias 95% LOA % in LOA 
Konelabserum 
vs SSXpwhole 
blood 
0.56± 
0.04 
0.47–0.65 85.72± 
11.91 
61.72–
109.7 
7.13 -209.7–
223.9 
98 
Konelabserum 
vs SSXpplasma 
0.48± 
0.04 
0.40–0.57 112.0± 
10.87 
90.6–
133.9 
20.23 -217.1–
257.5 
96 
SSXpwhole 
blood  
vs SSXpplasma 
0.80± 
0.05 
0.70–0.91 49.23± 
11.69 
25.67–
72.79 
-13.10 -116.5–
90.28 
98 
Table 5: Deming regression analysis results, depicting constant (intercept) and proportional (slope) 
error, with 95% confidence intervals. Bland-Altman data used to determine agreement between 
methodologies 
CI, confidence interval; LOA, limits of agreement 
 
Figure 1; Deming-regression plots between Konelab and (a) SSXpwhole blood and (b) SSXpplasma. Bland-
Altman difference plots between Konelab and (c) SSXpwhole blood and (d) SSXpplasma  
[Insert figure 1a] 
[Insert figure 1b] 
[Insert figure 1c] 
[Insert figure 1d] 
Figure 2; Deming-regression and Bland Altman difference plots demonstrating very high correlation (a) 
and agreement (b) respectively, between SSXpwhole blood and SSXpplasma creatinine values  
[Insert figure 2a] 
[Insert figure 2b] 
 
Discussion 
To the authors’ knowledge, this is the first study in which analytical and clinical performance of a 
hand-held PoC creatinine analyser has been evaluated for use in cats. 
 
Imprecision guidelines are provided by Westgard, the governing standard for analytical quality 
requirements, with desired within-run and between-run imprecision for serum creatinine of 2.98% 
and 3.96% respectively; indicating inadequate precision of the SSXp (within-run and between-run 
CV of 4.23-8.85% and 8.95-11.72% respectively), compared to laboratory standard.27 A recent study 
evaluating the SSXp in human patients (whole blood) reported comparable findings, with mean 
within-run imprecision of 2.3-5.9% and mean between-run imprecision (using three level QCM) of 
4.2-9.0%; therefore similarly failing to meet desired specifications.11 CV values for pooled feline 
serum (our study) and whole blood (previous human studies) were lower than for QCM.11 This is 
unexpected; the uniform matrix of the latter would be expected to yield a more consistent result 
compared with the less homogenous matrix of whole blood, plasma or serum.11 
 
Average TEobs (QCM: mean 29.36%, range 22.15-34.92%; feline serum pool: mean 25.87%, range 
19.78-29.39%) also failed to meet desired TEA (17, 20%).18,19,20 Possible explanations for this include 
machine, reagent strip, operator or environmental error; further work would be needed to identify 
which factors are most influential. Sigma metrics for the SSXp was consistent with very poor 
performance ( ≤3) at both creatinine TEA thresholds. A recent study evaluating the SSXp in human 
patients neither reported TEobs nor sigma metric values, so a direct comparison cannot be made.11 
Whilst creatinine is reported to be among those biochemical analytes having the greatest 
imprecision, bench-top veterinary devices perform considerably more precisely; a recent study 
evaluating analytical performance of a dry chemistry analyser reported TEobs and  for feline 
creatinine of 10 and 5.7 respectively.28,29  
 
The population of cats in our study had a serum creatinine range, as determined by Konelab, of 48-
1299µmol/l (0.54-14.69mg/dl). Despite being reported to measure creatinine over a range of 27-
1056µmol/l (0.31-11.95mg/dl), the SSXp range for the same population was from 63-682µmol/l 
(0.71-7.71mg/dl) and 73-664µmol/l (0.83-7.51mg/dl) for SSXpwhole blood and SSXpplasma respectively, 
indicating a failure of the SSXp to accurately quantify higher creatinine values. Further studies 
evaluating greater numbers of markedly azotemic samples are required to further elucidate the SSXp 
performance at high creatinine concentrations.   
 
Although SSXp is intended for creatinine measurement in whole blood, we also measured creatinine 
in plasma as the similar matrix of plasma and serum rendered comparison between SSXp and 
reference methodology more representative. Indeed, SSXpplasma exhibited greater correlation with 
Konelabserum (r = 0.91, P<0.0001) than did SSXpwhole blood with Konelabserum (r = 0.85, P<0.0001). 
 
The Konelabserum vs SSXpplasma and Konelabserum vs SSXpwhole blood regression plots revealed two 
(1299µmol/l vs 644µmol/l [14.69mg/dl vs 7.29mg/dl], 799µmol/l vs 408µmol/l [9.04mg/dl vs 
4.62mg/dl]) and one (1299µmol/l vs 601µmol/l [14.69mg/dl vs 6.80mg/dl]) data points 
respectively, markedly deviating from the line of best fit. Whilst the trend at lower creatinine values 
was for the SSXp (whole blood and plasma) to have a positive bias relative to the Konelab, this 
trended towards a considerable negative bias of SSXp compared with Konelab at higher creatinine 
values; with increased discordance associated with higher creatinine concentrations as indicated 
above. The reason for this switch from a positive to negative bias was not apparent and would require 
further investigation. Furthermore, this is of considerable importance when considering clinical 
applicability of the device; had a consistent positive or negative bias been identified, this may have 
enabled either generation of a device-specific reference range, or, application of a linear algorithm to 
SSXp results to yield greater correlation with reference methodology. However, the switch from a 
positive to negative bias makes exploring both of these options obsolete. The finding of a negative 
bias of the SSXp vs reference methodology at higher creatinine values was also identified in a recent 
human study; with demonstration of improved correlation if values >600µmol/l (>6.79mg/dl) were 
excluded from analysis (r of 0.99 and 0.97 respectively).11 The higher correlation in this previous 
study can be accounted for by excellent correlation at lower creatinine values, in comparison to the 
positive bias exhibited when SSXp is used to evaluate feline creatinine. Similarly, apparently higher 
correlation between reference methodology and SSXp evaluation of canine creatinine (r=0.954) in a 
previous study can be explained by a narrower range of creatinine values (maximum 610µmol/l 
[6.9mg/dl]).16 Discordance from laboratory methodology with increasing creatinine values has also 
been identified in earlier models of the SSXp.12,15 It is possible that unmeasured metabolites 
associated with azotemia cause interference with the methodology at higher creatinine values. These 
deviated data points also appeared as the only outliers on the Bland-Altman difference plots. If these 
outliers were excluded from analysis, this considerably narrowed the 95% limits of agreement, from 
424.9µmol/l (4.81mg/dl) with outliers, to 150.1µmol/l (1.70mg/dl) without outliers for Konelabserum 
vs SSXpwhole blood and from 464.8 µmol/l (5.26mg/dl) with outliers to 114.1µmol/l (1.29mg/dl) 
without outliers for Konelabserum vs SSXpplasma. 
 Comparing Konelabserum vs SSXpwhole blood, in 36/48 paired samples the same IRIS stage was 
established by both instruments. In the remaining 12 paired samples, the SSXp and Konelab IRIS 
stages differed by a single stage; in 6/12 the SSXp creatinine value would have resulted in a falsely 
diagnosed azotemia (SSXp stage 2 vs Konelab stage 1) and in 2/12 the SSXp failed to identify an 
azotemia (SSXp stage 1 vs Konelab stage 2 for both). These findings (36/48 correctly staged, 19/21 
azotaemic patients identified) demonstrate reasonable sensitivity (90%) and specificity (82%) of the 
SSXp for identification of azotemia as based on IRIS staging (creatinine ≥140µmol/l [≥1.6mg/dl]). 
 
Previous studies have considered variability between whole blood and plasma matrices and thus 
evaluated the impact of PCV on PoC testing, specifically regarding blood glucose and lactate 
concentrations.30,31 Regarding the former, previous studies have consistently identified an inverse 
correlation between HCT and blood glucose concentration; proposed mechanisms for this 
relationship include erythrocytes causing mechanical impedance of plasma diffusion into the reagent 
strip, blood viscosity affecting fluid permeability in the reagent layer and other matrix-associated 
complications (e.g. micro-clot formation, protein deposition, fibrin aggregation) or haemolysis.31 
Conversely, PCV does not appear to influence lactate measurement; with a lack of correlation 
reported (r = 0.04; P = 0.77; PCV range 14-57.5%). Our findings of no significant correlation between 
PCV and SSXpwhole blood (r = -0.28) suggest that within the tested range (18-42%), PCV does not 
significantly affect SSXp measurement of creatinine. Further testing would be required to evaluate 
the effect of severe anaemia or erythrocytosis. The previous study evaluating the SSXp in human 
patients used whole blood but did not evaluate the impact of PCV on creatinine determination.11 
 
Conclusions 
The SSXp was easy-to-use, providing rapid patient-side results. Precision studies identified poor 
repeatability and reproducibility, not meeting acceptable guidelines for a PoC device. Despite this, 
high to very-high correlation was exhibited, compared to the reference methodology for creatinine 
determination. The SSXp correctly classified the IRIS stage in 36/48 of patients, although 2/21 
azotemic cats were not identified. Improved device precision and accuracy are required prior to 
recommending its’ use in feline patients. 
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